echothiophate
Trade name: phospholine iodide
Approved
Jun 27, 1960
Echothiophate is a potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia. Echothiophate iodide for ophthalmic solution will depress both plasma and erythrocyte cholinesterase levels in most patients after a few weeks of eye drop therapy by binding irreversibly to cholinesterase, and thus long acting due to the slow rate of hydrolysis by cholinesterase. It causes miosis, increase in facility of outflow of aqueous humor, fall in intraocular pressure, and potentiation of accommodation. — NCATS
Clinical trial activity
1 trials · 1 clinical orgs · 2 marketing orgs
Earliest trial started Jun 1, 2016 (NCT02544529)
Timeline
1960s
- Jun 27, 1960
Wyeth — Earliest FDA Approval
- Jun 27, 1960
Wyeth — NDA Organization
- Jun 27, 1960
Wyeth — NDA Secondary Org
- Jun 27, 1960
Fera Development, LLC — Marketing Organization
- Jun 27, 1960
Fera Development, LLC — NDA Secondary Org
Indications
Studied for
Mechanism of action
- AcetylcholinesteraseINHIBITOR
ACHE inhibitor
Approval history
- approvedJun 27, 1960
Chemistry & pharmacology
SMILES
CCOP(=O)(OCC)SCC[N+](C)(C)C- Mol. weight
- 256.33 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL1201341 ↗
- WikipediaEchothiophate ↗
- NCATS0F350BVT6S ↗
- ChEMBLCHEMBL1200367 ↗
Also known as
- 2-(diethoxyphosphorylsulfanyl)ethyl-n,n,n-trimethylazanium iodide
- 2-(diethoxyphosphorylsulfanyl)ethyl-n,n,n-trimethylazanium iodide
- echothiophate
- echothiophate
- echothiophate
- echothiophate
- echothiophate
- echothiophate
- echothiophate
- echothiophate
- echothiophate iodide
- echothiophate iodide
- echothiophate iodide
- echothiophate iodide
- echothiophate iodide
- ecostigmine iodide
- ecostigmine iodide
- ecothiopate
- ecothiopate
- ecothiopate
- ecothiopate
- ecothiopate iodide
- ecothiopate iodide
- ecothiopatum
- ecothiopatum
- ecothiophate
- phospholine
- phospholine
- phospholine
- phospholine iodide
- phospholine iodide
- phospholine iodide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02544529 | Phase 4 | Jun 1, 2016 | Danbury Eye Physicians & Surgeons, PC |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Danbury Eye Physicians & Surgeons, PC | Academic/Hospital | 1 | 1 | 1 | 2016 |
Marketing (4)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Fera Development, LLC | For profit | MKTG | Jun 27, 1960 |
| Fera Development, LLC | For profit | NDA2 | Jun 27, 1960 |
| Wyeth | For profit | NDA | Jun 27, 1960 |
| Wyeth | For profit | NDA2 | Jun 27, 1960 |